DEVINA BHASIN: Open Payments
NPI 1063607109 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$9,820 in 60 payments from 18 companies in 2025. Trend: 2023 $759 · 2024 $14,293 · 2025 $9,820
Speaker / faculty: $6,620Food & beverage: $1,779Travel & lodging: $1,421
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 17 | $8,471 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $194 |
| Amgen Inc. | 3 | $175 |
| Fujifilm Healthcare Americas Corporation | 1 | $154 |
| Madrigal Pharmaceuticals | 4 | $135 |
| Mallinckrodt Hospital Products Inc. | 5 | $124 |
| Novo Nordisk Inc | 2 | $112 |
| ABBVIE INC. | 1 | $107 |
| TriSalus Life Sciences, Inc. | 3 | $69 |
| Ipsen Biopharmaceuticals, Inc | 2 | $48 |
Products named: Livdelzi, XIFAXAN, UTASWAKO AFP-L3, REZDIFFRA, TERLIVAZ, MAVYRET, TRINAV INFUSION SYSTEM, IQIRVO.
Industry payments across GA — which companies pay providers there.
